Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA filed separate lawsuits against the provision last month.

Johnson & Johnson sued the Biden administration over Medicare’s new powers to slash drug prices, making it the third pharmaceutical company to challenge the controversial provision of the Inflation Reduction Act.

  • @cydEnglish
    7•1 year ago

    The rejoinder is that other countries manage not to get ripped off. The US was previously (stupidly) banned from negotiating drug prices, but now that it can negotiate in earnest like other countries, why shouldn’t it get at least as good a deal as other countries, simply by negotiating normally? If anything, the sheer size of Medicare should mean that it can get better deals. So why put in these excess measures that invite legal challenge? It seems strange to me.